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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether or not besifloxacin
ophthalmic suspension 0.6% is safe and effective for the treatment of bacterial conjunctivitis.
STUDY DESIGN: Review of three trials in the English language, all published in 2009.
DATA SOURCES: Randomized, double masked, multicenter parallel group studies comparing
besifloxacin to a vehicle suspension or moxifloxacin were found using Ovid MEDLINE, and
Cochrane databases.
OUTCOME MEASURED: Resolution of bacterial conjunctivitis through reduced or eliminated
signs or symptoms, the microbial eradication of the bacteria responsible for the disease, and the
safety of the medication used in terms of adverse events while treating bacterial conjunctivitis
with besifloxacin.
RESULTS: All three double blinded RCTs demonstrated that besifloxacin was more safe and
effective in treating bacterial conjunctivitis when compared with a vehicle suspension. When
besifloxacin was compared with moxifloxacin, it was concluded that besifloxacin is not inferior
to moxifloxacin for the treatment of bacterial conjunctivitis.
CONCLUSIONS: The results of the RCTs demonstrate that besifloxacin for the treatment of
bacterial conjunctivitis is safe and effective. More studies are needed comparing other drug
treatments, different strengths, the safety and efficacy in children versus adults and the duration
of the medicine adminitaration. Future studies will help to determine the best medicinal option in
treating bacterial conjunctivitis safely and effectively.
KEY WORDS: Besifloxacin, Bacterial Conjunctivitis
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Introduction
Bacterial conjunctivitis, whether acute or chronic is the most common eye disorder that
nearly everyone will face at least once in their lifetime. Bacterial conjunctivitis is a disease that
is symptomatically defined by a copious purulent discharge, mild eye discomfort due to sticky
eyelids, redness and ocular irritation. The most common organisms to cause bacterial
conjunctivitis are Staphylococci, Streptococci, Haemophilus, Pseudomonas, and Moraxella. In
many cases, bacterial conjunctivitis is obtained from upper respiratory infections that have
spread to the eye, although there are other ways of transmitting the disease. Many bacterial
conjunctivitis cases are also due to transmission from an infected person to another through
infected areas and close personal contact. Moreover, conjunctivitis can also exist due to viruses.
Viral conjunctivitis is distinguished from bacterial conjunctivitis due to its characteristic clear
discharge.1
This eye disease is of great importance to primary care patients due to the high
prevalence of the disease. Due to its ability to affect anyone in all age groups, bacterial
conjunctivitis is important to treat and prevent. Although it is a self limiting disease in most
cases, the use of antibiotics for its treatment has ultimately led to reduced transmission, quicker
recovery time, shorter duration of the disease and reduced complications from long standing
disease.2 Prevention of bacterial conjunctivitis is also possible through management of associated
diseases such as acute otitis media and bacterial pneumonia, which can result in bacterial
conjunctivitis if untreated.1
Currently, methods that are used to treat bacterial conjunctivitis include topical
antibiotics such as sulfacetamide 10%, polymixin-bacitracin-neomycin, and trimethoprimpolymixin. Broad spectrum topical antibiotics are sufficient to treat the disease and cultures of
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the ocular discharge are done to determine antibiotic resistance or in cases refractory to
medicinal treatment. The total direct and indirect cost of treating bacterial conjunctivitis in the
United States in 2005 was estimated to be $589 million.2 Costs include primary care visits and
the cost of medicinal treatment, primarily topical broad spectrum antibiotics.
Besifloxacin is another topical antibiotic that can be used as an option to treat those who
have been affected by bacterial conjunctivitis. Besifloxaxin is a fluoroquinolone that has fairly
good broad spectrum antibiotic activity. It is an FDA approved drug for the treatment of bacterial
conjunctivitis, that has shown success in treating bacterial conjunctivitis as well as preventing
complications and reducing transmission as well as duration of the disease.
Objective
The goal of this review is to determine whether or not besifloxacin ophthalmic
suspension 0.6% is safe and effective for the treatment of bacterial conjunctivitis. Previous
randomized controlled trials that have been published on besifloxacin ophthalmic suspension
0.6% for the treatment of bacterial conjunctivitis have shown that besifloxaxin is a safe and
effective treatment and can be used as an alternative to other topical antibiotics for the treatment
of bacterial conjunctivitis.
Methods
The studies that were obtained for this analysis were RCT’s that included patients over
the age of 1 who were adequately diagnosed with bacterial conjunctivitis based on criteria set
forth by the studies’ authors. The intervention that was utilized in each of these RCT’s was
besifloxacin ophthalmic suspension 0.6%. Comparisons to this intervention included
moxifloxaxin ophthalmic suspension 0.5%, another fluoroquinolone in the treatment of bacterial
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conjunctivitis and a vehicle suspension that did not include besifloxacin. To gather information
on these studies, databases such as the Cochrane Database of Systematic Reviews, MEDLINE,
and the Ovid interface were used. All articles that were chosen were selected based on their
importance of the outcomes to patients. Inclusion criteria that were placed for the selection of the
studies were: 1) studies that were published in 1996 or later. 2) Studies associated with POEMS.
3) Studies published in the English language. 4) Studies that were randomized controlled trials.
4) Studies that were not previously used in meta-analyses or systematic reviews. Searching for
randomized controlled studies in English using the keywords “besifloxacin,” and “bacterial
conjunctivitis” helped to selectively limit articles that were necessary and were of importance to
the study. The studies that were finalized and chosen were: 1) Randomized, prospective, double
masked, vehicle controlled trial comparing besifloxacin suspension 0.6% to a vehicle
formulation without besifloxacin. 2) Multicenter, randomized, double masked, parallel group
study comparing besifloxacin ophthalmic suspension 0.6% to moxifloxacin ophthalmic solution
0.5%. and 3) Randomized, multicenter, double-masked, vehicle controlled study that compared
besifloxacin ophthalmic suspension 0.6% to a vehicle suspension without besifloxacin.
The characteristics of all the studies that were used in this analysis are displayed in Table
1. The three RCT’s are similar in inclusion and exclusion criteria. Interventions are also similar
in all the trials. The number of participants in each study varies greatly, as well as the number of
withdrawals from the trials.

Table 1. Characteristics of Studies Included in the Systematic Review of Besifloxacin
Ophthalmic Suspension 0.6% for the Treatment of Bacterial Conjunctivitis
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Study

Type

# Pts.

Age
(yrs)

Inclusion
Criteria

Exclusion
Criteria

W/D

Intervention

1+

Minimum grade
1 for purulent
conjunctival
discharge,
minimum grade 1
for either bulbar
or palpebral
conjunctival
injection, pinhole
visual acuity ≥
20/200, negative
pregnancy test

Hypersensitivity to
fluroquinolones,
besifloxacin, or
any other
ingredient used in
the study, if a
topical medication
was used within
48 hours before or
during study, if
Abx were used
w/in 72 hrs of the
start of study, dx
of viral/allergic
conjunctivitis, hx
of iritis, corneal
erosion syndrome,
ulcerative keratitis
Use of ophthalmic
solutions, ocular
surgery within 6
weeks of start of
study,
viral/allergic
conjunctivitis,
ulcerative keratitis,
corneal erosion
syndrome,
hypersensitivity to
drug/drug class
Use of systemic or
topical Abx within
72 hrs, topical soln
within 2 hours,
anti-inflamm.
agent within 48
hrs before or
during the study,
pregnant or
nursing females,
viral/allergic
conjunctivitis,
corneal erosion
syndrome,
ulcerative keratitis,
immunocompromi
sed,
hypersensitivity to
drug/drug class

13

Besifloxacin
ophthalmic
suspension 0.6%
given 3 times
daily for 5 days

Karpecki,
et.al.,
2009

RCT,
double
masked

269

McDonald
,et al.,
2009

RCT,
double
masked

1161

1+

Healthy pts,
grade 1 or more
purulent
discharge and
injection, visual
acuity of ≥
20/200,
agreement to d/c
Abx agents,
negative
pregnancy test

Tepedino,
et al.,
2009

RCT,
double
masked

957

1+

Visual acuity ≥
20/200, method
of contraception
or negative
pregnancy test,
discontinued use
of contact lenses

52

Besifloxacin
ophthalmic
suspension 0.6%
given 3 times
daily for 5 days

26

Besifloxacin
ophthalmic
suspension 0.6%
applied 3 times
daily for 5 days
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Outcomes that were measured were POEMS such as the resolution of bacterial
conjunctivitis through reduced or eliminated signs or symptoms, the microbial eradication of the
bacteria that was the cause of the disease, and the safety of the medication used in treating
bacterial conjunctivitis. Outcomes were measured using Cochran-Mantel-Haenszel (CMH),
Pearson X2 test, Fisher exact test, individual safety outcomes assessments based on grading
scales. Karpecki, DePaolis, Hunter, White, et al used 4 point scales for ocular discharge, bulbar
conjunctival injection, where 0= absent, 1= mild, 2= moderate, and 3=severe. The clinical
outcomes were then counted for each patient, and an overall score was determined. In the overall
score, 0= scores for ocular discharge and bulbar conjunctival injection are 0, 1= improvement,
current score less than day-1 score, 2= no change from baseline score, 3= worse, current score
greater than day-1 score. In the study done by McDonald, Protzko, Brunner, Morris, et al, the
investigators used a scale to determine global assessment of changes in clinical signs and
symptoms where 0= cured, 1= improved, 2= no change from pretreatment, and 3= worse.
Investigators Tepedino, Heller, Usner and Brunner, et al also used the same 0-3 rating scale for
clinical outcomes where 0= resolution or cure, 1=improvement, 2= no change, and 3= worse.
In all three RCT’s, microbial eradication was measured through microscopy. Safety was
measured in all studies using visual acuity and biomicroscopy for lids, limbus, conjunctiva,
cornea, anterior chamber, lens and vitreous.
Results
Two RCT’s compared besifloxacin with a vehicle suspension while another RCT
compared besifloxacin with moxifloxacin, another topical ophthalmic antibiotic in the same drug
class. Inclusion and exclusion criteria for each of the studies was fairly similar. Each study chose
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participants who were above the age of 1 and healthy, non pregnant patients. The participants
also had to have a minimum grade 1 for purulent ocular discharge and a minimum grade 1 for
bulbar or palpebral conjunctival injection along with a pinhole visual acuity of greater than
20/200. The study excluded participants who had a hypersensitivity to fluoroquinolones, if the
patients had used any topical medication on the eye within 48 hours of the start of the study, if
antibiotics were used within 72 hours of the study or if the patient had a diagnosis of viral or
allergic conjunctivitis. Patients with a history of corneal erosion syndrome, ulcerative keratitis,
or iritis were also excluded from the studies.
The results of the primary outcome, the treatment of bacterial conjunctivitis were
presented in the articles as dichotomous data. All data from the studies were analyzed with the
intention to treat, excluding those who were excluded from the study.
In the investigation done by Karpecki et al, the clinical resolution of bacterial
conjunctivitis was 43.1% and 73.3% in the control and besifloxacin groups respectively. The
relative benefit increase (RBI) was 70.0%, and the absolute benefit increase (ABI) was 30.2%.
The number needed to treat (NNT) was 4 patients. The difference in the control and experimental
groups is statistically significant with the p-value less than 0.001.3
In the study done by McDonald et al, the clinical resolution of bacterial conjunctivitis
was 84% in the moxifloxacin group, and 84.5% in the besifloxacin group. The relative benefit
increase and absolute benefit increase was 0.60% and 0.5% respectively. The number needed to
treat was 200 patients. All data was included in a 95% confidence interval for RBI and ABI.4
The investigation done by Tepedino et al in comparing a vehicle suspension with
besifloxacin ophthalmic suspension 0.6% yielded a clinical resolution and microbial eradication

Desai, Besifloxacin & Bacterial Conjunctivitis 7

of bacterial conjunctivitis of 69.1% in the control group, and 84.4% in the besifloxacin group.
The relative risk benefit and absolute benefit increase is 22% and 15.3% respectively. The
number needed to treat was 7 patients. All data was statistically significant with a p-value of
0.0011.5 Table 2 shows a summary of all three studies and the results for the clinical resolution
of bacterial conjunctivitis in each study.
Table 2. Clinical Resolution of Bacterial Conjunctivitis with Besifloxacin Suspension 0.6%
Study

Besifloxacin Control
group
group
resolution resolution
of illness
of illness
73.3%
43.1%

p-value

Odds
Ratio
(95% CI)

RBI

ABI

NNT

Karpecki,
<0.0001
NR
70.0%
30.2%
4*
2009
McDonald,
84.5%
84%
NR
(-5.6%0.60%
0.5%
200*
2009
6.75%)
Tepedino,
84.4%
69.1%
0.0011
NR
22%
15.3%
7*
2009
CI= Confidence Interval, RBI= Relative Benefit Increase, ABI= Absolute Benefit Increase,
NNT= Number Needed to Treat, NR= Not Reported
* The outcome that was measured was the clinical resolution of bacterial conjunctivitis. The
NNT means that for every 4/200/7 patients who participated and received besifloxacin treatment,
there was one more resolution of bacterial conjunctivitis than in the group of patients taking the
vehicle suspension or the moxifloxacin suspension.
Each study also calculated the incidence of adverse effects in terms of safety of
besifloxacin ophthalmic suspension 0.6%. In the study done by Karpecki et al, the incidence of
adverse events for besifloxacin group was 50.4%, and was 53% for the control group. The
relative risk increase (RRI) was -4.9%, and the absolute risk increase (ARI) was -3.0%. The
number needed to harm is -34 patients.
In the study completed by McDonald et al, the incidence of ocular adverse events was
12% in the besifloxacin group and 14% in the control group with moxifloxacin. The relative risk
increase was -14.3% and the absolute risk increase was -2.0%. The number needed to harm was

Desai, Besifloxacin & Bacterial Conjunctivitis 8

-50 patients.4
Tepedino et al completed a study between a vehicle suspension and besifloxacin
ophthalmic suspension 0.6% in which the incidence of adverse events for the besifloxacin group
was 9.2% and the adverse events for the control group, or the vehicle suspension without
besifloxacin was 13.9%. The relative risk increase was calculated to be 33.8% and the absolute
risk increase was calculated as -4.7%. The number needed to harm in this study was -22 patients.
The data in this study was statistically significant with a p-value of 0.0047. Table 3 shows a
summary of the incidence of adverse events in patients with besifloxacin and in the control group
for each study performed.5
Table 3- Incidence of Adverse Events of Besifloxacin and Control Groups
Study

Besifloxacin
Incidence of
Adverse
Events

Control
Group
Incidence
of Adverse
Events
53%

p-value

RRI

ARI

NNH

Karpecki,
50.4%
NR
-4.9%
-3.0%
-34*
2009
McDonald,
12%
14%
NR
-14.3%
-2.0%
-50*
2009
Tepedino,
9.2%
13.9%
0.0047
-33.8%
-4.7%
-22*
2009
RRI= Relative Risk Increase, ARI= Absolute Risk Increase, NNH= Number Needed to Harm,
NR= Not Reported
* Since the outcome measured were adverse events in those participants receiving besifloxacin
ophthalmic suspension 0.6%, the values mean that for every -34/-50/-22 patients treated with
besifloxacin, there was one fewer incidence of adverse events experienced than in the group
receiving the vehicle solution.
In all three studies performed with besifloxacin, the most common adverse event that was
reported was ocular irritation. Patients reported itching of the eyes or irritation after
administration of the medication. However, in all three studies, the incidence of adverse events
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in the besifloxacin group were significantly lower than the incidence of adverse events in the
control group, whether it be a vehicle suspension without besifloxacin or moxifloxacin. The most
common adverse events that were reported in each of the studies was eye irritation, blurred
vision and ocular pruritis. Karpecki and associated analyzed ocular adverse events in the
experimental and control groups. They determined that the overall ocular adverse event rate in
the eyes that were treated with besifloxacin was 34.7%, whereas the ocular adverse event rate in
the eyes that were treated with vehicle suspension not containing besifloxacin was 38.8%. Table
3 displays the results of the ocular adverse events that occurred during the Karpecki et al study
on besifloxacin.3
Table 3. Incidence of Ocular Adverse Events in Besifloxacin and Vehicle Suspension Groups
Ocular Adverse Event
Eye Pain
Blurred Vision
Eye Irritation
n= number of participants

Besifloxacin (n=190)
20 (10.5%)
20 (10.5%)
14 (7.4%)

Vehicle (n=188)
13 (6.9%)
22 (11.7%)
23 (12.2%)

Discussion
In the double masked RCT that was conducted by Karpecki and associates, the results
displayed success for the besifloxacin intervention. The clinical resolution of bacterial
conjunctivitis was 73.3% for the besifloxacin experimental group whereas the resolution of
bacterial conjunctivitis was 43.1% for the vehicle suspension group. Both interventions were
administered similarly 3 times a day for 5 days.3 McDonald et al determined in their double
blinded RCT that moxifloxacin and besifloxacin were similar in efficacy due to their similar
properties. The clinical resolution for besifloxacin and moxifloxacin was 58.3% and 59.4%
respectively. The solutions were also used three times daily for a total of 5 days. The study also
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noted that the 95% Confidence Interval of the clinical resolution rates showed that besifloxacin
was not inferior to moxifloxacin despite a difference in their success rates.4 The administration
of besifloxacin and a vehicle suspension for three times daily for five days in the Tepedino et al
double blinded study also yielded results in favor of the besifloxacin intervention. The clinical
resolution of bacterial conjunctivitis in the besifloxacin group and in the vehicle group without
besifloxacin was 45.2% and 33.0% respectively.5
All three of the RCTs included a patient population over the age of 1. However, there is
no information on the results of clinical resolution and adverse events of besifloxacin between
children and adults. More information is needed on the efficacy of the medication between the
two groups as well as the strength and the administration of the medication that can be given to
children versus adults. This information will likely allow primary care providers to determine if
besifloxacin is safe and effective for children also.
Authors of the RCT also mentioned that besifloxacin, a fluoroquinolone was effective in
eradicating the bacteria that are the most likely causes for bacterial conjunctivitis.
Fluroquinolones cover Gram positive bacteria as well as Gram negative bacteria, and the
efficacy of besifloxacin in the microbial resolution of the bacterial conjunctivitis is vital
information on treating most cases of bacterial conjunctivitis.
A limitation of each study was the comparison of clinical resolution rates between
treating bacterial conjunctivitis symptomatically with no medication and using besifloxacin for
treating bacterial conjunctivitis from Day 1. There is no information on how the outcome of the
disease would have been in regards to duration of the disease if besifloxacin was not used for
five days to treat the illness. A study comparing the duration of the disease in using besifloxacin
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versus no medication would be helpful to determine if bacterial conjunctivitis is a disease to be
treated with medications or not.
Conclusions
The trials that were reviewed established that besifloxacin is safe and effective in treating
bacterial conjunctivitis. Since besifloxacin suspension was only studied using one strength,
0.6%, there was a limitation in knowing the efficacy at different strengths of the medication.
Future studies should be designed to include different classes of drugs that can be used to treat
bacterial conjunctivitis. The length of the administration of the medication should also vary to
determine the recommended duration of treatment. The results of these future studies will help to
determine the best medicinal option in the treatment of bacterial conjunctivitis.
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